ArticlePrecision radiation oncology2026
Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol.
Article in Precision radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980259 (Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial
Who cites it
2 citing papers in PubMed.
- Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design.Current oncology (Toronto, Ont.) · 2026Review
- Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol.Precision radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Soft tissue sarcoma (STS) is a rare and highly heterogeneous malignancy. Conventional radiotherapy (CRT) often shows limited efficacy, especially in radioresistant subtypes, such as liposarcoma and fibrosarcoma, with local recurrence rates ranging from 10% to 30%. Spatially fractionated radiotherapy (SFRT), a technique that delivers non-uniform high-dose distributions, has shown promise in improving tumor control and potentially stimulating immune responses in preliminary studies. Methods: This multicenter, prospective, randomized phase II trial aims to enroll 106 patients aged 18-70 years with pathologically confirmed STS and a minimum tumor diameter ≥5 cm. Participants will be randomized 1:1 into SFRT or CRT groups. CRT involves a uniform dose of 3.0 Gy per fraction over 15-20 fractions. SFRT employs a non-uniform dose distribution, supplementing CRT with high-dose spot irradiation of 8-15 Gy per fraction delivered for a total of 3-4 fractions. The primary endpoint was the objective response rate, and the secondary endpoints included local control, progression-free survival, and safety. Discussion: This trial is the first randomized study to directly compare SFRT and CRT for STS. SFRT is expected to enhance tumor control and elicit immunomodulatory effects, particularly in radioresistant tumors. However, the potential acute toxicities and technical complexities warrant further evaluation. Future studies should investigate the synergistic potential of SFRT combined with immunotherapy. Trial registration: The study was registered at ClinicalTrials.gov with the Identifier: NCT06980259 (Registered 12th May 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.